Literature DB >> 33077619

The Impact of Circulating Antibody on Group B Streptococcus Intestinal Colonization and Invasive Disease.

Michelle J Vaz1, Sheryl A Purrier2, Maryam Bonakdar3, Anna B Chamby4, Adam J Ratner5,6, Tara M Randis7,8.   

Abstract

Gastrointestinal (GI) colonization with group B Streptococcus (GBS) is an important precursor to late-onset (LO) disease in infants. The host-pathogen interactions that mediate progression to invasive disease remain unknown due, in part, to a paucity of robust model systems. Passively acquired maternal GBS-specific antibodies protect newborns from early-onset disease, yet their impact on GI colonization and LO disease is unexplored. Using murine models of both perinatal and postnatal GBS acquisition, we assessed the kinetics of GBS GI colonization, progression to invasive disease, and the role of GBS-specific IgG production in exposed offspring and juvenile mice at age 12 and 14 days, respectively. We defined LO disease as >7 days of life in the perinatal model. We studied the impact of maternal immunization using a whole-cell GBS vaccine on the duration of intestinal colonization and progression to invasive disease after postnatal GBS exposure in offspring. Animals exhibit sustained GI colonization following both perinatal and postnatal exposure to GBS, with 21% and 27%, respectively, developing invasive disease. Intestinal colonization with GBS induces an endogenous IgG response within 20 days of exposure. Maternal vaccination with whole-cell GBS induces production of GBS-specific IgG in dams that is vertically transmitted to their offspring but does not decrease the duration of GBS intestinal colonization or reduce LO mortality following postnatal GBS exposure. Both perinatal and postnatal murine models of GBS acquisition closely recapitulate the human disease state, in which GBS colonizes the intestine and causes LO disease. We demonstrate both endogenous production of anti-GBS IgG in juvenile mice and vertical transfer of antibodies to offspring following maternal vaccination. These models serve as a platform to study critical host-pathogen interactions that mediate LO GBS disease.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Streptococcus agalactiae (group B Streptococcus [GBS]); antibody; late-onset sepsis; neonates

Mesh:

Substances:

Year:  2020        PMID: 33077619      PMCID: PMC7927928          DOI: 10.1128/IAI.00348-20

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  Colonisation of babies and their families by group B streptococci.

Authors:  A M Weindling; J M Hawkins; M A Coombes; J Stringer
Journal:  Br Med J (Clin Res Ed)       Date:  1981-12-05

2.  Group B streptococcus late-onset disease: 2003-2010.

Authors:  Alberto Berardi; Cecilia Rossi; Licia Lugli; Roberta Creti; Maria Letizia Bacchi Reggiani; Marcello Lanari; Luigi Memo; Maria Federica Pedna; Claudia Venturelli; Enrica Perrone; Matilde Ciccia; Elisabetta Tridapalli; Marina Piepoli; Raffaella Contiero; Fabrizio Ferrari
Journal:  Pediatrics       Date:  2013-01-06       Impact factor: 7.124

3.  Vaginal memory T cells induced by intranasal vaccination are critical for protective T cell recruitment and prevention of genital HSV-2 disease.

Authors:  Ayuko Sato; Aldina Suwanto; Manami Okabe; Shintaro Sato; Tomonori Nochi; Takahiko Imai; Naoto Koyanagi; Jun Kunisawa; Yasushi Kawaguchi; Hiroshi Kiyono
Journal:  J Virol       Date:  2014-09-17       Impact factor: 5.103

4.  A bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi.

Authors:  Ying-Jie Lu; Fan Zhang; Sabina Sayeed; Claudette M Thompson; Shousun Szu; Porter W Anderson; Richard Malley
Journal:  Vaccine       Date:  2012-03-29       Impact factor: 3.641

5.  The surface protein HvgA mediates group B streptococcus hypervirulence and meningeal tropism in neonates.

Authors:  Asmaa Tazi; Olivier Disson; Samuel Bellais; Abdelouhab Bouaboud; Nicolas Dmytruk; Shaynoor Dramsi; Michel-Yves Mistou; Huot Khun; Charlotte Mechler; Isabelle Tardieux; Patrick Trieu-Cuot; Marc Lecuit; Claire Poyart
Journal:  J Exp Med       Date:  2010-10-18       Impact factor: 14.307

6.  Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection.

Authors:  C J Baker; D L Kasper
Journal:  N Engl J Med       Date:  1976-04-01       Impact factor: 91.245

7.  Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005.

Authors:  Christina R Phares; Ruth Lynfield; Monica M Farley; Janet Mohle-Boetani; Lee H Harrison; Susan Petit; Allen S Craig; William Schaffner; Shelley M Zansky; Ken Gershman; Karen R Stefonek; Bernadette A Albanese; Elizabeth R Zell; Anne Schuchat; Stephanie J Schrag
Journal:  JAMA       Date:  2008-05-07       Impact factor: 56.272

8.  Maternal antibody at delivery protects neonates from early onset group B streptococcal disease.

Authors:  Carol J Baker; Vincent J Carey; Marcia A Rench; Morven S Edwards; Sharon L Hillier; Dennis L Kasper; Richard Platt
Journal:  J Infect Dis       Date:  2013-10-16       Impact factor: 5.226

9.  Association between antibodies against group B Streptococcus surface proteins and recto-vaginal colonisation during pregnancy.

Authors:  Sonwabile Dzanibe; Gaurav Kwatra; Peter V Adrian; Sheila Z Kimaro-Mlacha; Clare L Cutland; Shabir A Madhi
Journal:  Sci Rep       Date:  2017-11-28       Impact factor: 4.379

10.  Association between functional antibody against Group B Streptococcus and maternal and infant colonization in a Gambian cohort.

Authors:  Kirsty Le Doare; Amadou Faal; Mustapha Jaiteh; Francess Sarfo; Stephen Taylor; Fiona Warburton; Holly Humphries; Jessica Birt; Sheikh Jarju; Saffiatou Darboe; Edward Clarke; Martin Antonio; Ebenezer Foster-Nyarko; Paul T Heath; Andrew Gorringe; Beate Kampmann
Journal:  Vaccine       Date:  2017-04-24       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.